GSK Agrees to Acquire RAPT Therapeutics for $2.2 Billion
San Francsico – January 20, 2026 – Cooley advised RAPT Therapeutics (NASDAQ: RAPT), a California-based, clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients living with inflammatory and immunologic diseases, on its definitive agreement to be acquired by GSK. Under the terms of the agreement, GSK will pay RAPT Therapeutics shareholders $58 per share in cash at closing for an estimated aggregate equity value of $2.2 billion.
Partners Jamie Leigh, Bill Roegge, Lindsey O’Crump and Courtney Tygesson led the Cooley team advising RAPT.
Cooley previously advised RAPT on its initial public offering and subsequent private investments in public equity (PIPEs) and follow-on offerings, including a $250 million follow-on offering in October 2025 and $150 million PIPE in December 2024.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.
Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.
Related Contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.